司美格鲁肽 (诺和诺德)(Semaglutide (Novo Nordisk)) - 药物靶点：GLP-1R_在研适应症：慢性肾病，脑卒中，心肌梗塞_专利_临床

概要

基本信息

药物类型

合成多肽

别名

Semaglutide、Semaglutide (Genetical Recombination)、Semaglutide (genetical recombination) (JAN)

+ [24]

靶点

GLP-1R

作用机制

GLP-1R激动剂(胰高血糖素样肽-1激动剂)

治疗领域

内分泌与代谢疾病神经系统疾病心血管疾病+ [7]

在研适应症

非在研适应症

原研机构

在研机构

Gilead Sciences, Inc.Merck Sharp & Dohme LLC

+ [6]

非在研机构-

最高研发阶段批准上市

首次获批日期

美国 (2017-12-05),

2型糖尿病

最高研发阶段(中国)批准上市

特殊审评突破性疗法 (中国)

登录后查看时间轴

结构/序列

Sequence Code 50953

来源: *****

关联

508

项与司美格鲁肽 (诺和诺德) 相关的临床试验

NCT06801015

/ Not yet recruiting临床4期IIT

A Randomized, Placebo-Controlled Trial of the Effects of Long-Acting GLP-1 or Dual Incretin (GLP-1 and GIP) Modulation on Gastric Motor Functions

The purpose of this study is to compare effects of weekly SQ semaglutide 2.4mg SQ, SQ tirzepatide 10mg, and placebo administered for 24 weeks on GES measured repeatedly at baseline, 16 weeks, 24 weeks, 28 weeks, 4 weeks after stopping the medication, and accommodation and satiation at 24 weeks compared to baseline.

开始日期2025-04-15

申办/合作机构

Mayo Clinic

NCT05689372

/ Not yet recruitingN/A

A Multi-centre, Prospective, Open-label, Single-arm, Non-interventional, Regulatory Post Marketing Surveillance (rPMS) Study of Ozempic Solution for Injection 1.34mg/ml (Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea

The aim of this study is to assess the safety and effectiveness of Ozempic initiated according to label in adults with Type 2 Diabetes Mellitus (T2DM) under routine clinical practice conditions. Participants will get Ozempic as prescribed by study doctor. The study will last for about 26 weeks.

开始日期2025-03-31

申办/合作机构

Novo Nordisk A/S

NCT05714683

/ Not yet recruitingN/A

A Multi-centre, Prospective, Open-label, Single-arm, Non-interventional, Regulatory Post Marketing Surveillance (rPMS) Study of Rybelsus® (Oral Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea

The aim of this study is to assess the safety and effectiveness of Rybelsus initiated according to label in adults with Type 2 Diabetes Mellitus (T2DM) under routine clinical practice conditions. Participants will get Rybelsus as prescribed by study doctor. The study will last for about 26 weeks.

开始日期2025-03-31

申办/合作机构

Novo Nordisk A/S

100 项与司美格鲁肽 (诺和诺德) 相关的临床结果

登录后查看更多信息

100 项与司美格鲁肽 (诺和诺德) 相关的转化医学

登录后查看更多信息

100 项与司美格鲁肽 (诺和诺德) 相关的专利（医药）

登录后查看更多信息

1,692

项与司美格鲁肽 (诺和诺德) 相关的文献（医药）

2025-12-31·Journal of Pharmaceutical Policy and Practice

Compounded glucagon-like peptide-1 receptor agonists for weight loss: the direct-to-consumer market in Colorado

Article

作者: Saseen, Joseph J. ; Dardouri, Mouna ; Nair, Kavita V. ; Moore, Gina D. ; DiStefano, Michael J.

Background:

High prices and other access barriers have contributed to the rise of a market for compounded glucagon-like peptide-1 receptor agonists for weight loss in the United States. This market has not been systematically studied. We conducted a pilot study to assess the prevalence, characteristics, and advertising content of direct-to-consumer providers of compounded glucagon-like peptide-1 products for weight loss in Colorado.

Methods:

We conducted a cross-sectional study of websites advertising compounded glucagon-like peptide-1 products for weight loss in Colorado. Websites were identified using Google searches focused on census-defined statistical areas. Searches were conducted between March 21 and April 12, 2024. Data collected from websites included physical addresses, business type, highest reported staff credential, advertised glucagon-like peptide-1 products, whether businesses referred to Food and Drug Administration approval when describing products, and whether businesses referred to products as 'generic'.

Results:

We identified 93 business websites advertising compounded glucagon-like peptide-1 products for weight loss corresponding to 188 physical locations throughout Colorado. Most businesses were self-categorized as medical/health spas (33/93) or weight loss services (26/93). Advertised products included semaglutide (92/93), tirzepatide (40/93), liraglutide (2/93), and retatrutide (1/93). Advertised combination products included B vitamins (8/93), levocarnitine (1/93), mannitol (1/93), BPC-157 (1/93), and glycine (1/93). Seven websites advertised oral formulations. Additionally, 41/93 websites referred to Food and Drug Administration approval in their descriptions of compounded products and 5/93 referred to products as 'generic'.

Conclusion:

This study identified several instances of unapproved glucagon-like peptide-1 products being compounded and advertised in Colorado. Additionally, 1 product was advertised as compounded with BPC-157, a substance determined by the Food and Drug Administration to be unsafe for compounding. This study also identified numerous examples of misleading claims regarding the regulatory status of compounded glucagon-like peptide-1 products. Regulatory action is needed to ensure the benefits of compounded GLP-1 products outweigh the risks.

2025-03-01·METABOLISM-CLINICAL AND EXPERIMENTAL

Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis

Review

作者: Fragakis, Nikolaos ; Mantzoros, Christos S ; Karakasis, Paschalis ; Patoulias, Dimitrios

BACKGROUND AND AIMS:

While glucagon-like peptide-1 receptor agonists (GLP-1RAs) effectively reduce body weight, their impact on lean mass remains uncertain. This meta-analysis evaluated the effects of GLP-1RAs and GLP-1/GIP receptor dual agonists (GLP-1/GIP-RAs) on body composition, focusing on total weight, fat mass, and lean mass in adults with diabetes and/or overweight/obesity.

METHODS:

A systematic search of Medline, Embase, and the Cochrane Library was conducted through November 12, 2024. Data were analyzed using random-effects pairwise and network meta-analyses to compare interventions with placebo or active comparators.

RESULTS:

Twenty-two randomized controlled trials (2258 participants) were included. GLP-1RAs significantly reduced total body weight (MD -3.55 kg, 95 %-CI [-4.81, -2.29]), fat mass (MD -2.95 kg, 95 %-CI [-4.11, -1.79]), and lean mass (MD -0.86 kg, 95 %-CI [-1.30, -0.42]), with lean mass loss comprising approximately 25 % of the total weight loss. However, the relative lean mass, defined as percentage change from baseline, was unaffected. Liraglutide, at 3.0 mg weekly or 1.8 mg daily, was the only GLP-1RA to achieve significant weight reduction without significantly reducing lean mass. Tirzepatide (15 mg weekly) and semaglutide (2.4 mg weekly) were the most effective for weight and fat mass reduction but were among the least effective in preserving lean mass.

CONCLUSIONS:

Potent GLP-1 RAs, such as tirzepatide and semaglutide, demonstrate greater overall weight loss but are associated with a significant reduction in lean mass.

2025-03-01·Endocrine Metabolic & Immune Disorders-Drug Targets

Efficacy and Safety of Semaglutide in Weight Loss of Non-diabetic People

Article

作者: Wu, Hong-Yan ; Song, Cai-E ; Dai, Xue-Mei ; Wang, Yan

Objective::

The study aimed to investigate the efficacy and safety of semaglutide in weight loss in non-diabetic people.

Methods::

In this study, 84 non-diabetic people who used semaglutide to lose weight in the outpatient department of our hospital from January 1, 2022, to June 30, 2022, were enrolled and compared for changes in body weight, waist circumference, Body Mass Index (BMI), fasting blood glucose, blood pressure, pulse, and body composition (body fat ratio, visceral fat area, and skeletal muscle) before treatment and 12 weeks after the treatment to analyze the weight loss efficacy and safety.

Results::

After administering semaglutide 0.25 mg, 0.5 mg, 0.75 mg, or 1.0 mg subcutaneously once a week for 12 weeks, 84 participants in this study obtained an average weight loss of 5.91 ± 3.37 kg, equivalent to 6.15 ± 4.28% of baseline body weight, and there was also a significant reduction in visceral fat area and a slight reduction in blood pressure. The most common adverse reactions included gastrointestinal reactions (nausea, vomiting, and diarrhea), which were mild and subsided within 1-2 days. No severe adverse reaction, such as hypoglycemia and hypotension, was observed.

Conclusion::

Low-dose semaglutide has been found to be effective and safe for short-term weight loss in non-diabetic people.

4,590

项与司美格鲁肽 (诺和诺德) 相关的新闻（医药）

21 小时之前

·SYNAPSE

2025年2月6日全球新药进展早知道

1. FDA批准罗氏雷珠单抗植入剂新适应症，治疗糖尿病黄斑水肿 2月4日，罗氏宣布，FDA已批准Susvimo（雷珠单抗植入剂）100 mg/mL用于治疗糖尿病黄斑水肿（DME）。DME是导致糖尿病患者视力丧失的主要原因，全球有超过2900万成年人受此影响。Susvimo是首个也是唯一一个相较于标准眼内注射治疗能够以更少的治疗次数维持DME患者视力的FDA获批疗法。FDA的批准基于III期Pagoda研究的积极一年结果，该研究显示Susvimo在DME患者中表现出持续的视力改善，且安全性与Susvimo已知的安全性一致。Susvimo是罗氏为实现缓释以减轻患者多次眼部玻璃体内注射雷珠单抗的痛苦而开发的一款剂型创新产品，通过港式给药系统（Port Delivery Platform）持续向患者眼内递送雷珠单抗，一年仅需植入两次。 2. 美国FDA批准皮下帕金森疗法 2月4日，Supernus Pharmaceuticals公司（NASDAQ:SUPN）宣布，FDA批准ONAPGO（盐酸阿扑吗啡）注射液（原名SPN-830）作为第一种也是唯一一种阿扑吗啡皮下输注设备，用于治疗晚期帕金森病（PD）成人的运动波动。消息发布后，该公司股价上涨7%，收于40美元。Onapgo 是一种皮下设备，允许持续输注多巴胺激动剂盐酸阿波吗啡，以减少 “关期” 发作。关期是指在白天和夜晚服药间隔期间，左旋多巴药物效果减退，不良运动功能症状（运动障碍）加重的时期。在临床试验中，Onapgo（原名 SPN-830）与安慰剂治疗相比，显著减少了这些每日关期发作的平均时间，减轻了 2.47 小时，而安慰剂治疗仅减少了 0.58 小时。 3. 司美格鲁肽在欧美地区申报3项新适应症 2月5日，诺和诺德公布2024年业绩，其中披露了司美格鲁肽的多个重要进展，包含3项新适应症的监管申请提交：1）降糖版司美格鲁肽（Ozempic）治疗外周动脉疾病（PAD）的新适应症已在欧美地区进行申报。此次申报主要基于IIIb期STRIDE研究；2）口服司美格鲁肽（Rybelsus）降低T2D患者发生重大不良心血管事件（MACE）风险的新适应症已在欧美地区进行申报，这些患者已确诊心血管疾病（CVD）和/或慢性肾病（CKD）。此次申报主要基于III期SOUL研究。3）减肥版司美格鲁肽（Wegovy）治疗肥胖相关射血分数保留型心衰（HFpEF）的新适应症申请在美国重新递交。此外，诺和诺德也表示，在未来几个月内，用于减重的口服司美格鲁肽25mg将申报上市。2024年6月，诺和诺德已成功完成口服司美格鲁肽25mg用于减重的IIIb期OASIS 4研究。 4. 辉瑞终止B7-H4 ADC开发，10亿美元无形资产减值 2月4日，辉瑞公布2024 Q4财报，并更新了其管线进展。根据报道，辉瑞公司已经终止了B7-H4 ADC药物felmetatug vedotin的开发，由此引发了10亿美元的无形资产减值。B7H4V（felmetatug vedotin）采用MMAE作为毒素，在三阴乳腺癌和HR阳性HER2阴性的乳腺中表现出20%以上的响应率，在B7-H4 高表达患者中同时表现出更佳的疗效。辉瑞在2023年底收购Seagen时获得了该ADC。 5. 一款TIL细胞管线研发终止 2月4日，Turnstone生物制药公司因制造成本过高，终止了其最后一个临床阶段的肿瘤浸润淋巴细胞（TIL）疗法项目TIDAL-01，并计划进一步裁员。此举紧随该公司去年十月裁员60%之后，旨在最大限度地提高股东价值。TIDAL-01 是其目前唯一一个临床实验项目，正在多个 I 期临床试验中进行评估，用于治疗包括转移性结直肠癌、头颈癌和葡萄膜黑色素瘤等实体肿瘤。在 STARLING I 期临床试验中，TIDAL-01 在转移性结直肠癌患者中显示出积极的初步数据。在四个可评估的微卫星稳定转移性结直肠癌（MSS mCRC）患者中，客观缓解率（ORR）达到 25%，疾病控制率（DCR）为 50%。 6. 新型非阿片类小分子药物2期临床结果积极 2月4日，Algiax Pharmaceuticals公司宣布，在研疗法AP-325在治疗神经性疼痛的2a期临床试验中获得积极顶线数据。研究显示，该公司这一主打候选药物不仅有望迅速减轻神经性疼痛，还能在治疗后为患者带来持久的益处。AP-325起效迅速，在治疗不足两周内，疼痛强度数字评估量表（PI-NRS）显示具有临床意义的疼痛缓解。研究结束时，超过四分之一的AP-325组患者疼痛缓解达到或超过50%，而安慰剂组仅为11%。AP-325是一种GABAA受体的正向别构调节剂（PAM），是一种非阿片类小分子药物，旨在通过激活GABAA信号通路来缓解神经性疼痛。神经性疼痛是一种慢性疾病，常常与兴奋性和抑制性神经信号失衡有关。新闻稿指出，通过持续对抗神经的过度激活，AP-325有可能革新神经性疼痛的治疗方式。 7. 信达生物「信迪利单抗」联合疗法拟纳入优先审评，针对结肠癌 2月5日，CDE官网最新公示，信达生物申报的伊匹木单抗和信迪利单抗拟纳入优先审评，适应症为伊匹木单抗注射液联合信迪利单抗用于可切除的微卫星高度不稳定型（MSI-H）或错配修复缺陷型（dMMR）结肠癌患者的新辅助治疗。公开资料显示，这是信达生物在研的抗CTLA-4单抗IBI310与抗PD-1单抗信迪利单抗联合疗法，该联合疗法此前已经被CDE纳入突破性治疗品种。 1. Auron Therapeutics完成2700万美元B轮融资，开发抗癌蛋白降解剂 2月4日，Auron Therapeutics公司宣布，该公司完成2700万美元的B轮融资。同时，其潜在“first-in-class”的KAT2A/B蛋白降解剂AUTX-703的IND申请已经获得美国FDA的许可。该公司正在启动AUTX-703治疗血液恶性肿瘤的临床试验。本次B轮融资由DCVC Bio领投，并得到了Apollo Health Ventures、Arkin Bio Ventures、BrightEdge、Casdin Capital、Franklin Berger、Mubadala Capital、Polaris Partners以及启明创投美国部的支持。融资获得的资金将用于推进AUTX-703在急性髓系白血病（AML）患者中进行的1期临床概念验证试验，该试验将于今年第一季度开始患者招募。 2. 30亿欧元！赛诺菲从欧莱雅强力回购股份近日，赛诺菲从欧莱雅处回购了欧莱雅所持有的约2.3%赛诺菲股份，售价为每股101.5欧元，交易总额达到30亿欧元（约合31.1亿美元）。赛诺菲在另一份声明中表示，此次交易也是其50亿欧元股票回购计划中的一部分。交易完成后，欧莱雅将继续持有赛诺菲7.2%的股份和13.1%的投票权。据了解，这笔交易将在未来几天内通过场外大宗交易完成。 3. 默沙东暂停向中国市场供应HPV疫苗 2月4日，默沙东在公布2024年财报的同时宣布，因中国市场对HPV疫苗需求疲弱，为加速库存消耗，将暂停向中国市场供应GARDASIL HPV宫颈癌疫苗。据默沙东刚刚公布的2024年财报显示，其全年总营收达到641.68亿美元，同比增长7%，制药业务收入574.00亿美元，同比增长7%。K药以293亿美元再度登顶药王，另一当家产品HPV疫苗（GARDASIL/GARDASIL 9），2024全年销售额仅86亿美元，同比下降了3%。首席财务官Caroline Litchfield表示，其在中国的分销商（重庆智飞生物）的出货量「大幅下降」，导致GARDASIL的库存水平「高于正常水平」。内容来源于网络，如有侵权，请联系删除。

临床结果临床研究抗体药物偶联物优先审批融资引进/卖出

2025-02-05

·药事纵横

诺和诺德2024年财报：司美格鲁肽大卖近300亿美元

2月5日，丹麦诺和诺德公司正式公布了2024年年报。诺和诺德全年营收2904.03亿丹麦克朗（约合421.3亿美元），同比增长25%，营业利润1283.39亿丹麦克朗（约合186.2亿美元），同比增长25%，净利润1009.88亿丹麦克朗(约合146.5亿美元），同比增长21%。值得一提的是，诺和诺德的盈利水平（营业利润/销售额）高达44.19%，让美国哪些创新巨头望尘莫及。诺和诺德旗下有糖尿病与肥胖症护理、罕见病两大业务部门，其中营收主要来自糖尿病与肥胖症护理，2024年的总销售额达2717.64亿丹麦克朗，而罕见病仅为186.39亿丹麦克朗。 GLP-1是诺和诺德最大的“印钞机”，Rybelsus（口服司美格鲁肽）2024年卖出233.01亿丹麦克朗（约合33.80亿美元），Ozempic（注射司美格鲁肽）卖出1203.42亿丹麦克朗（约合174.59亿美元），Wegovy（减肥版司美格鲁肽）也卖出582.06亿丹麦克朗（约合84.44亿美元），司美格鲁肽的合计销售额达292.8亿美元，虽然表现非常抢眼，但并没有取代K药成为新一代药王。除了司美格鲁肽，诺和诺德的GLP-1还包括上一代的利拉鲁肽，Victoza（利拉鲁肽降糖）和Saxenda（利拉鲁肽减肥）也分别卖出54.82亿丹麦克朗（约合7.95亿美元）和69.40亿丹麦克朗（约合10.07亿美元）。胰岛素是诺和诺德第二大“印钞机”，2024年总销售额为553.73亿丹麦克朗（约合80.33亿美元），得益于德古胰岛素的拉动，胰岛素总销售额相比去年同期增长了15.3%。三大长效胰岛素 Tresiba（德古胰岛素）、Xultophy（德古胰岛素/利拉鲁肽）和Levemir（地特胰岛素）分别卖出99.05亿丹麦克朗、46.68亿丹麦克朗和45.03亿丹麦克朗。两大预混胰岛素Ryzodeg（德古胰岛素/门冬胰岛素）和NovoMix（预混门冬胰岛素/精蛋白门冬胰岛素）的营收分别为49.29亿丹麦克朗和58.60亿丹麦克朗，业绩表现为前者升后者降。速效胰岛素方面，两大产品 Fiasp（超速效门冬胰岛素配方）和NovoRapid（门冬胰岛素）合计卖出185.22亿丹麦克朗，相比去年同期增加约26亿丹麦克朗。除了以上三代胰岛素，诺和诺德仍在销售二代人胰岛素，其销售额为69.67亿丹麦克朗，销售规模也出现了同比下跌。罕见病方面，诺和诺德的产品管线主要为凝血因子、生长激素等产品，全年营收仅为186.39亿丹麦克朗，在总销售额中的占比非常小，诺和诺德的产品销售额如下表所示：相比其他国际制药巨头，诺和诺德并未开展大规模并购，研发投入强度也仅维持在15%左右，但销售额的持续高速增长充分体现了该公司在产品开发方面的高效性。而这种高效性可以归结于四个方面：一是高度专注于糖尿病，上百年的知识积累，让诺和诺德对疾病有了深刻的理解，让专注变成了专长；二是重视用户体验，不做第一，只做最好，总结整个发展史，诺和诺德并没有推出过首创性（first-in-class）新药，但其推出的都是同领域最好、最便捷的产品，这或许与两家公司相互竞争时形成的文化有关；三是充分利用好手上的产品，让市场价值最大化，最具代表的案例就是利拉鲁肽，诺和诺德不仅开发了减肥针，与胰岛素做成了复方，还积极开展了大量临床试验，证明了产品除降糖外，还具有心血管获益、肾脏功能获益的优势，大大增强了产品的市场竞争力；四是重视平台技术的发展，因为拥有先进的脂肪酸酰化技术、多肽口服技术和酵母菌发酵技术，诺和诺德才具有足够的优势去赢得市场。药事纵横征稿启事

财报并购

2025-02-05

·Business Wire

AgelessRx Expands Offerings to Include Oral GLP-1 Drops to Advance Metabolic Health and Longevity Science

ANN ARBOR, Mich.--( BUSINESS WIRE )-- AgelessRx , a pioneer in longevity and telehealth solutions, announced the introduction of oral sublingual drops for GLP-1 receptor agonists Semaglutide and Tirzepatide. By offering non-injectable alternatives to medications that may support metabolic health management 1 and counter the effects of aging 2 , AgelessRx continues to empower individuals to live longer, healthier lives. Optimal metabolic health is a foundational component of longevity. Dysregulated glucose levels, visceral fat accumulation, and other markers of poor metabolic function accelerate biological aging and increase the risk of chronic diseases, such as cardiovascular disease, Type 2 diabetes, and liver disease, making GLP-1s critical for overall health and healthspan. “Our mission is to make longevity accessible for all, and GLP-1s are a core piece of that puzzle,” said Stefanie Morgan, Vice President of Applied Sciences at AgelessRx. “The impact of these medications is proving to go beyond traditional uses to significantly improve key health metrics - from metabolic health, to glucose regulation, liver function 34 , heart health, and even sleep 56 - that could be foundational to a long, healthy life and a key driver in longevity.” Recent research shows that about one in eight adults have taken a GLP-1 in their lifetime. Unlike conventional approaches, these medications may do more than manage symptoms - they may work at a biological level to support overall health. These benefits directly contribute to increased healthspan by potentially delaying the onset of chronic diseases and supporting cellular resilience. Compounded with a SubMagna SL HMW, AgelessRx’s sublingual methods bypass digestion for quicker, more efficient delivery into the bloodstream as compared to other oral methods such as digestible tablets. As a longevity-focused telehealth platform, AgelessRx’s Stanford PhD-led Applied Sciences team is actively exploring the broader applications of GLP-1s in promoting lifespan and longevity. The introduction of oral GLP-1s reflects the company’s dedication to the core principles of longevity - prevention of chronic conditions through better metabolic control, personalization of care to meet individual health needs, and proactivity in empowering individuals to take charge of their long-term well-being. By making these transformative therapies more accessible and adaptable to individual needs, AgelessRx is helping to bring longevity-focused care within reach for millions. For additional information about AgelessRx and its longevity-promoting products and services, please visit agelessrx.com . Discover more about the benefits and details of Oral Tirzepatide Drops and Oral Semaglutide Drops through the links provided. About AgelessRx AgelessRx is at the forefront of the longevity revolution, offering clinically validated cutting-edge solutions and preventive treatments aimed at extending life expectancy and enhancing quality of life. AgelessRx also continues to advance the field of longevity science by conducting ongoing research and clinical trials . Through its online platform, AgelessRx provides easy access to innovative healthcare services, with an emphasis on customer satisfaction, affordability, and the pursuit of a future where extended healthspan is a reality for everyone. Follow AgelessRx on Instagram , X , and Facebook . ___________________ 1 MacDonald, P. E. et al. The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion. Diabetes 51, S434–442 (2002). 2 SGLT2 inhibitors and GLP-1 receptor agonists: which is the best anti-frailty drug? Mone, Pasquale et al. The Lancet Healthy Longevity, Volume 5, Issue 9, 100632 3 Targher, G., Mantovani, A. & Byrne, C. D. Mechanisms and possible hepatoprotective effects of glucagon-like peptide-1 receptor agonists and other incretin receptor agonists in non-alcoholic fatty liver disease. Lancet Gastroenterol. Hepatol. 8, 179–191 (2023). 4 Romero-Gómez, M. et al. A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease. J. Hepatol. 79, 888–897 (2023). 5 de Lemos, J. A. et al. Tirzepatide reduces 24-hour ambulatory blood pressure in adults with body mass index ≥27 kg/m(2): SURMOUNT-1 ambulatory blood pressure monitoring substudy. Hypertension 81, e41–e43 (2024). 6 Malhotra A, Grunstein RR, Fietze I, Weaver TE, Redline S, Azarbarzin A, Sands SA, Schwab RJ, Dunn JP, Chakladar S, Bunck MC, Bednarik J; SURMOUNT-OSA Investigators. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med. 2024 Oct 3;391(13):1193-1205. doi: 10.1056/NEJMoa2404881.

临床2期

100 项与司美格鲁肽 (诺和诺德) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10025	司美格鲁肽 (诺和诺德)	A10BJ06	DB13928

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
慢性肾病	美国	Novo Nordisk A/S	2025-01-28
脑卒中	澳大利亚	Novo Nordisk Pharmaceuticals Pty Ltd.	2024-12-16
心肌梗塞	加拿大	Novo Nordisk Canada, Inc.	2024-11-27
肥胖	美国	Novo Nordisk, Inc.	2021-06-04
超重	美国	Novo Nordisk, Inc.	2021-06-04
2型糖尿病	美国	Novo Nordisk, Inc.	2017-12-05

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
血管疾病	临床3期	美国	Novo Nordisk A/S	2023-03-01
血管疾病	临床3期	日本	Novo Nordisk A/S	2023-03-01
血管疾病	临床3期	阿根廷	Novo Nordisk A/S	2023-03-01
血管疾病	临床3期	澳大利亚	Novo Nordisk A/S	2023-03-01
血管疾病	临床3期	巴西	Novo Nordisk A/S	2023-03-01
血管疾病	临床3期	保加利亚	Novo Nordisk A/S	2023-03-01
血管疾病	临床3期	加拿大	Novo Nordisk A/S	2023-03-01
血管疾病	临床3期	哥伦比亚	Novo Nordisk A/S	2023-03-01
血管疾病	临床3期	丹麦	Novo Nordisk A/S	2023-03-01
血管疾病	临床3期	法国	Novo Nordisk A/S	2023-03-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04916470 (STEP-HFpEF DM, Pubmed) 人工标引	临床3期	2型糖尿病 \| 射血分数保留型心力衰竭	616	Semaglutide 2.4 mg (low baseline HbA1c group)	蓋襯蓋餘顧膚遞齋壓製(鏇簾觸鏇襯構構衊膚憲) = 獵膚製壓獵餘鏇憲淵壓窪積夢齋窪範積壓製齋 (壓蓋膚顧築憲積襯製鹹, 8.8 ~ 16.0) 更多	积极	2025-01-20
				Placebo (low baseline HbA1c group)	蓋襯蓋餘顧膚遞齋壓製(鏇簾觸鏇襯構構衊膚憲) = 淵鬱願鹹鹹繭繭積餘網窪積夢齋窪範積壓製齋 (壓蓋膚顧築憲積襯製鹹, 2.1 ~ 9.2) 更多
NCT05646706 (STEP UP, NEWS) 人工标引	临床3期	肥胖	-	Semaglutide 7.2 mg	壓廠範鹽鏇願淵鏇醖蓋(廠襯窪膚鹽積網襯願襯) = 顧夢構憲醖醖網夢積鑰齋鬱範遞顧鹹艱醖窪蓋 (糧鬱顧願鏇窪遞鹹衊製 ) 更多	积极	2025-01-17
				Semaglutide 2.4 mg	壓廠範鹽鏇願淵鏇醖蓋(廠襯窪膚鹽積網襯願襯) = 餘構壓夢範網餘遞夢顧齋鬱範遞顧鹹艱醖窪蓋 (糧鬱顧願鏇窪遞鹹衊製 ) 更多
NCT05259033 (COMBINE 2, Pubmed \| Diabetologia)	临床3期	2型糖尿病 GLP-1 receptor agonist	683	IcoSema	簾餘鹽鏇蓋憲顧糧餘遞(鬱淵構糧顧鹽夢齋廠鏇) = 製願繭鏇廠淵簾鹽繭醖壓衊積構淵獵鏇獵繭製 (廠構廠願夢憲簾醖觸鏇 )	积极	2025-01-17
NCT05259033 (COMBINE 2, CTgov)	临床3期	2型糖尿病	683	IcoSema (IcoSema)	遞襯製糧醖簾觸網顧遞(艱餘糧憲鏇獵壓築遞淵) = 鑰顧鹽觸鹽鑰鏇鑰壓膚築廠獵網製齋醖獵憲顧 (衊積構獵廠醖膚衊構憲, 醖網憲築選鏇網願艱鏇 ~ 膚淵鬱壓鑰獵齋積醖願) 更多	-	2025-01-17
				Semaglutide 1 mg (Semaglutide)	遞襯製糧醖簾觸網顧遞(艱餘糧憲鏇獵壓築遞淵) = 餘簾獵蓋鹽構構壓衊衊築廠獵網製齋醖獵憲顧 (衊積構獵廠醖膚衊構憲, 壓獵願選襯製夢鏇鹽膚 ~ 醖鬱遞範築蓋選範憲顧) 更多
NCT05205928 (Pubmed \| Nat Med)	临床2/3期	1型糖尿病	28	Semaglutide 1 mg	鹹壓鑰齋顧鬱鏇觸顧蓋(網糧顧網齋夢窪範壓憲) = there were two episodes of recurrent euglycemic ketosis without acidosis during semaglutide use 築壓獵餘鹽築窪構壓窪 (鹹積選獵艱構廠襯醖蓋 )	积极	2025-01-10
NCT05822830 (SURMOUNT-5, Company_Website) 人工标引	临床3期	肥胖	751	Zepbound (tirzepatide)	憲繭齋淵製積範蓋醖夢(膚艱顧觸網鹹製願窪積) = 願築憲餘窪鑰鹹製積廠鏇窪願鹹齋憲獵網繭餘 (鹹衊鏇衊鑰蓋淵齋襯糧 ) 更多	优效	2024-12-04
				Wegovy (semaglutide)	憲繭齋淵製積範蓋醖夢(膚艱顧觸網鹹製願窪積) = 憲鬱艱遞淵鏇範積選夢鏇窪願鹹齋憲獵網繭餘 (鹹衊鏇衊鑰蓋淵齋襯糧 ) 更多
NCT04251156 (STEP7, CTgov)	临床3期	2型糖尿病 \| 肥胖	375	Semaglutide (Semaglutide 2.4 mg)	簾築齋窪衊醖鑰憲鏇齋(鬱構顧憲選獵願鑰觸鏇) = 顧簾窪蓋積淵構夢鏇鬱鹹鹹積製鏇襯餘餘鹹繭 (築鏇製壓顧壓鏇壓網廠, 鹽築選顧鬱遞憲蓋淵淵 ~ 範積築膚艱糧製淵製淵) 更多	-	2024-11-29
				placebo+semaglutide (Placebo)	簾築齋窪衊醖鑰憲鏇齋(鬱構顧憲選獵願鑰觸鏇) = 淵夢醖繭醖醖鹽築襯衊鹹鹹積製鏇襯餘餘鹹繭 (築鏇製壓顧壓鏇壓網廠, 糧夢鹹鬱鏇窪餘淵廠鬱 ~ 鑰夢選範壓窪遞製遞構) 更多
Pubmed 人工标引	N/A	酒精使用障碍	227,866	Semaglutide	願願鹽廠製製鬱艱壓糧(選觸糧醖壓選膚廠襯襯) = A total of 133 210 individuals (58.5%) experienced AUD hospitalization. Semaglutide (4321 users) was associated with the lowest risk (AUD: adjusted hazard ratio [aHR], 0.64; 95% CI, 0.50-0.83) and use of liraglutide (2509 users) with the second lowest risk (AUD: aHR, 0.72; 95% CI, 0.57-0.92) of AUD hospitalization. 夢鹽選餘構衊願製膚壓 (鏇選顧憲鬱艱簾遞餘鑰 ) 更多	积极	2024-11-13
				Liraglutide
NCT04560998 (STRIDE, NEWS \| Corporate Publications) 人工标引	临床3期	外周动脉疾病	-	Ozempic (semaglutide)	夢選觸構憲範膚蓋廠願(鬱窪鹹範壓簾夢蓋醖選) = 選構膚簾襯窪淵遞艱觸選糧遞積齋蓋壓憲鏇製 (鑰窪鹽鏇觸顧鑰製夢範 )	积极	2024-11-07
				Placebo	夢選觸構憲範膚蓋廠願(鬱窪鹹範壓簾夢蓋醖選) = 觸壓糧顧醖廠遞鹹獵鹹選糧遞積齋蓋壓憲鏇製 (鑰窪鹽鏇觸顧鑰製夢範 )
NCT06489457 (Pubmed \| Diabetes Obes Metab)	临床3期	-	25	Semaglutide 1 mg/week	觸鹹鏇餘壓夢製顧夢齋(醖壓製夢鏇選壓壓積鏇) = 網製鹹窪繭艱蓋糧範鹽願鏇製簾獵廠夢齋構襯 (淵廠選餘積艱鑰鹽積顧, 2 ~ 5.5)	积极	2024-11-07
				Testosterone undecanoate 1000 mg/10-12 weeks	觸鹹鏇餘壓夢製顧夢齋(醖壓製夢鏇選壓壓積鏇) = 醖廠齋願壓鑰簾窪鏇選願鏇製簾獵廠夢齋構襯 (淵廠選餘積艱鑰鹽積顧, 2 ~ 3.5)